AssetMark Inc’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $31.1M | Buy |
123,655
+18,757
| +18% | +$4.04M | 0.05% | 273 |
|
|
2026
Q1 | $22.8M | Sell |
104,898
-3,145
| -3% | -$698K | 0.05% | 304 |
|
|
2025
Q4 | $24.7M | Buy |
108,043
+2,724
| +3% | +$621K | 0.05% | 283 |
|
|
2025
Q3 | $24.4M | Buy |
105,319
+4,896
| +5% | +$997K | 0.05% | 272 |
|
|
2025
Q2 | $18.6M | Sell |
100,423
-66,549
| -40% | -$12.4M | 0.04% | 294 |
|
|
2025
Q1 | $35M | Sell |
166,972
-680
| -0.4% | -$132K | 0.1% | 175 |
|
|
2024
Q4 | $29.8M | Buy |
167,652
+17,143
| +11% | +$3.15M | 0.08% | 188 |
|
|
2024
Q3 | $29.7M | Buy |
150,509
+11,893
| +9% | +$2.22M | 0.09% | 185 |
|
|
2024
Q2 | $23.8M | Buy |
138,616
+4,906
| +4% | +$813K | 0.07% | 204 |
|
|
2024
Q1 | $24.3M | Buy |
133,710
+3,263
| +3% | +$562K | 0.08% | 194 |
|
|
2023
Q4 | $20.2M | Buy |
130,447
+6,656
| +5% | +$970K | 0.07% | 204 |
|
|
2023
Q3 | $18.5M | Buy |
123,791
+1,447
| +1% | +$212K | 0.07% | 196 |
|
|
2023
Q2 | $16.5M | Buy |
122,344
+1,498
| +1% | +$220K | 0.06% | 202 |
|
|
2023
Q1 | $19.3M | Buy |
120,846
+6,262
| +5% | +$957K | 0.08% | 183 |
|
|
2022
Q4 | $18.5M | Buy |
114,584
+12,083
| +12% | +$1.85M | 0.08% | 180 |
|
|
2022
Q3 | $13.8M | Buy |
102,501
+5,911
| +6% | +$848K | 0.06% | 195 |
|
|
2022
Q2 | $14.8M | Buy |
96,590
+4,860
| +5% | +$743K | 0.07% | 194 |
|
|
2022
Q1 | $14.9M | Sell |
91,730
-21,776
| -19% | -$3.16M | 0.06% | 198 |
|
|
2021
Q4 | $15.4M | Sell |
113,506
-163
| -0.1% | -$19.3K | 0.06% | 194 |
|
|
2021
Q3 | $12.3M | Buy |
113,669
+1,965
| +2% | +$225K | 0.05% | 208 |
|
|
2021
Q2 | $12.6M | Sell |
111,704
-57,803
| -34% | -$6.51M | 0.06% | 214 |
|
|
2021
Q1 | $18.3M | Sell |
169,507
-390
| -0.2% | -$41.7K | 0.09% | 177 |
|
|
2020
Q4 | $18.2M | Sell |
169,897
-68,192
| -29% | -$6.55M | 0.1% | 167 |
|
|
2020
Q3 | $20.9M | Buy |
238,089
+90,918
| +62% | +$8.56M | 0.13% | 147 |
|
|
2020
Q2 | $14M | Sell |
147,171
-9,639
| -6% | -$849K | 0.1% | 170 |
|
|
2020
Q1 | $11.9M | Sell |
156,810
-2,513
| -2% | -$214K | 0.1% | 156 |
|
|
2019
Q4 | $14.1M | Buy |
159,323
+86,524
| +119% | +$7.18M | 0.11% | 173 |
|
|
2019
Q3 | $5.51M | Buy |
72,799
+26,027
| +56% | +$1.78M | 0.05% | 238 |
|
|
2019
Q2 | $3.4M | Buy |
46,772
+9,343
| +25% | +$734K | 0.03% | 246 |
|
|
2019
Q1 | $3.02M | Buy |
37,429
+2,770
| +8% | +$227K | 0.03% | 237 |
|
|
2018
Q4 | $3.19M | Sell |
34,659
-183,754
| -84% | -$16.2M | 0.03% | 229 |
|
|
2018
Q3 | $20.7M | Buy |
218,413
+17,483
| +9% | +$1.66M | 0.19% | 111 |
|
|
2018
Q2 | $18.6M | Buy |
200,930
+22,288
| +12% | +$2.18M | 0.18% | 114 |
|
|
2018
Q1 | $16.9M | Buy |
178,642
+63,704
| +55% | +$7M | 0.18% | 113 |
|
|
2017
Q4 | $11.1M | Sell |
114,938
-25,654
| -18% | -$2.42M | 0.11% | 154 |
|
|
2017
Q3 | $12.5M | Buy |
140,592
+80,496
| +134% | +$6.13M | 0.14% | 137 |
|
|
2017
Q2 | $4.36M | Buy |
60,096
+14,200
| +31% | +$955K | 0.05% | 193 |
|
|
2017
Q1 | $2.99M | Buy |
45,896
+13,304
| +41% | +$836K | 0.04% | 217 |
|
|
2016
Q4 | $2.04M | Sell |
32,592
-183
| -0.6% | -$11.2K | 0.03% | 221 |
|
|
2016
Q3 | $2.07M | Sell |
32,775
-6,713
| -17% | -$435K | 0.03% | 214 |
|
|
2016
Q2 | $2.44M | Buy |
39,488
+1,344
| +4% | +$81.9K | 0.04% | 201 |
|
|
2016
Q1 | $2.18M | Buy |
38,144
+14,231
| +60% | +$793K | 0.04% | 211 |
|
|
2015
Q4 | $1.42M | Sell |
23,913
-4,184
| -15% | -$241K | 0.03% | 241 |
|
|
2015
Q3 | $1.53M | Buy |
28,097
+1,527
| +6% | +$99.4K | 0.03% | 205 |
|
|
2015
Q2 | $1.78M | Sell |
26,570
-1,522
| -5% | -$99.4K | 0.04% | 215 |
|
|
2015
Q1 | $1.65M | Buy |
+28,092
| New | +$1.7M | 0.04% | 223 |
|
Other funds holding ABBV
ECSS
ATO
AssetMark Inc's ABBV Position: Q2 2026 in Review
AssetMark Inc increased its AbbVie (ABBV) stake by 18% in Q2 2026, buying an estimated $4.04M and bringing the position to 123,655 shares worth $31.1M. The position accounts for 0.05% of the portfolio, ranked #273.
AssetMark Inc first reported a position in ABBV in Q1 2015 and has held it in 46 quarters since. The position peaked at $35M in Q1 2025. 1,993 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- AssetMark Inc held 123,655 shares of AbbVie worth $31.1M as of Q2 2026.
- AssetMark Inc bought 18,757 AbbVie shares in Q2 2026, an estimated $4.04M.
- AbbVie made up 0.05% of AssetMark Inc's portfolio in Q2 2026, its #273 holding.
- AssetMark Inc first reported a position in AbbVie in Q1 2015 and has held it in 46 quarters since.
- AssetMark Inc's AbbVie position peaked at $35M in Q1 2025.
- 1,993 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.